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Abstract
Background: Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma derived from skeletal muscle precursor
cells, which accounts for 5-8% of all childhood malignancies. Disseminated RMS represents a major clinical
obstacle, and the need for better treatment strategies for the clinically aggressive alveolar RMS subtype is
particularly apparent. Previously, we have shown that the acridine-4-carboxamide derivative AS-DACA, a known
topoisomerase II poison, is potently cytotoxic in the alveolar RMS cell line RH30, but is 190-fold less active in the
embryonal RMS cell line RD. Here, we investigate the basis for this selectivity, and demonstrate in these RMS lines,
and in an AS-DACA- resistant subclone of RH30, that AS-DACA-induced cytotoxicity correlates with the induction of
DNA double strand breaks.
Results: We show that inhibition of the multidrug-resistance associated protein (MRP1) has no effect on AS-DACA
sensitivity. By exploiting the pH-dependent fluorescence properties of AS-DACA, we have characterized its intracellular
distribution, and show that it concentrates in the cell nucleus, as well as in acidic vesicles of the membrane trafficking
system. We show that fluorescence microscopy can be used to determine the localization of AS-DACA to the nuclear
and cytoplasmic compartments of RMS cells grown as spheroids, penetrance being much greater in RH30 than RD
spheroids, and that the vesicular signal leads the way into the spheroid mass. EEA1 and Rab5 proteins, molecular
markers expressed on early-endosomal vesicles, are reduced by > 50% in the sensitive cell lines.
Conclusion: Taking the evidence as a whole, suggests that endosomal vesicle trafficking influences the toxicity of
AS-DACA in RMS cells.
Background
Rhabdomyosarcoma (RMS) is a malignant tumour
derived from primitive rhabdomyeloblasts with differen-
tiation towards skeletal muscle [1]. RMS makes up more
than half of the soft tissue sarcomas in children, and
accounts for 5-8% of all childhood malignancies [2].
Combination chemotherapy, following surgery, involving
drugs which inhibit mitotic spindle function, poison
topoisomerase II, inhibit transcription, and alkylate DNA,
has resulted in five-year survival rates of about 65% for
patients with localised RMS tumours [3]. However, the
presence of metastatic or disseminated disease, or a diag-
nosis of the alveolar RMS subtype, confers a worse prog-
nosis [4-7], with tumours often refractory to established
chemotherapy. Clearly, new agents are a priority, espe-
cially for the 30-40% of paediatric patients with these
malignancies who do not achieve full remission, or who
relapse following therapy.
Recently, we have shown that the acridine-4-carboxa-
mide derivative AS-DACA (Figure 1A), elicits a marked
differential response in several commonly studied rhabdo-
myosarcoma cell lines [8]. AS-DACA is potently cytotoxic
in the RMS-derived cell line RH30, but is 190-fold less
active in the RD cell line [8]. In this work we begin an
investigation into the basis for this preferential activity
between these two cell lines. AS- DACA is the 9-amino-5-
methylsulphone derivative of the clinical candidate DACA
[9,10], it has good solid tumour activity in animal models
[10], intercalates into DNA as a lipohilic monocation at
physiological pH with its charged N,N-dimethylethylamino
side chain binding to guanine [10-12], and poisons topoi-
somerase II [13]. It has the unusual property amongst the
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m o p h o r ei sw e a k l yb a s i cw i t hap Ko f5 . 2[ 1 0 ] ,s ot h a ta t
pH 7.4 it is a monocation, but as the pH is lowered
towards 6 and below, it becomes doubly charged. This has
consequences for its fluorescence properties, which
become pH-dependent, and may affect its intracellular dis-
tribution and pharmacology.
Here we use the fluorescence properties of AS-DACA to
permit direct visualization of its intracellular distribution.
A novel situation is therefore created whereby the cyto-
toxic agent itself reveals the pH of the organelle in which
it is localized. Our results show that AS-DACA not only
accumulates in the nucleus, as expected, but also in acidic
intracellular vesicles in RMS cells. However, we find that
the membrane trafficking system differs between the two
RMS subtypes, with the early endosome markers, Rab5
and EEA1, expressed to a lesser degree in the sensitive
RH30 cell line compared to the resistant RD cell line. Gen-
eration of an AS-DACA-resistant RH30 subline resulted in
an increase in expression of the early endosome markers,
Rab5 and EEA1, suggesting that the membrane trafficking
system plays a significant role in the determination of AS-
DACA sensitivity. In addition, we show that cytotoxic sen-
sitivity to AS-DACA correlates with the induction of DNA
double strand breaks, but is un-perturbed by the inhibition
of the multidrug-resistance associated protein MRP1.
Lastly, we demonstrate that fluorescence microscopy can
be used to examine the intracellular distribution of AS-
DACA into both the nuclear and cytoplasmic compart-
ments of RMS cells grown as spheroids, where penetrance
is much greater in RH30 than RD spheroids, and that the
vesicular signal leads the way into the spheroid mass.
Results
In previous work we showed that the IC50 for AS-DACA
in RD cells is 3800 ± 130 nM whereas in RH30 cells it is
20 ± 0.73 nM, indicating a 190-fold difference in sensitiv-
ity (Figure 1B) [8]. To help understand the reasons for
the sensitivity difference between these ERMS and the
ARMS cell lines, we developed an AS-DACA-resistant
sub-line of RH30 cells. Results from the MTT viability
assay highlight the significant level of resistance achieved
in the RH30 sub-line (Figure 1C). This cell line, desig-
nated Resistant- RH30 or “Res30”, expresses a stable phe-
notype in which the IC50 for AS-DACA is 9000 nM,
making it 450-fold more resistant to AS-DACA than its
parent (p value = 0.009, Students t-test). Importantly, the
cells retained their resistant phenotype over time. Cyto-
toxicity measurements reveal that Res30 cells have no
cross-resistance to the topoisomerase II poisons doxoru-
bicin and mitoxantrone (Figure 1D) (p value = 0.918 and
0.325 respectively, Students t-test), and that 9-amino-
DACA, a potent cytotoxic AS- DACA analogue lacking
the 5-methylsulphone group [14], shows only a limited
Figure 1 AS-DACA resistance in rhabdomyosarcoma cells. (A) Structure of AS- DACA. (B) MTT cell viability results presented as cytotoxicity
curves for AS-DACA in RD and RH30. (C) Derivation of the AS-DACA-resistant RMS cell line, Res30. Dose- response curves from MTT cell viability
assays performed at various stages in the development of AS-DACA-resistant RH30 cells. (D) Cytotoxicity curves of (i) 9-amino- DACA, (ii)
doxorubicin, and (iii) mitoxantrone in Res30 cells. Error bars are SEM for independent experiments performed in triplicate.
Wolf et al. BMC Cell Biology 2011, 12:36
http://www.biomedcentral.com/1471-2121/12/36
Page 2 of 114.4-fold loss of potency (p value = 0.001, Students t-test).
Given that AS-DACA induces cell death as a result of the
accumulation of DNA double strand breaks due to the
poisoning of topoisomerases [14], we investigated the
level of such strand breaks induced by AS- DACA in the
RMS cells by measuring the level of phosphorylation of
histone H2A.X (Ser139), known as gH2A.X, which is a
well-established marker of DNA double strand breaks
[15,16]. Phosphorylation was assessed over 48 h in all cell
lines following exposure to AS-DACA at a low dose,
equivalent to the IC50 for RH30 cells (20nM). The results
are expressed as a percentage of the DNA damage
observed, compared, over the equivalent time, to that
c a u s e db yad o s eo f4μMA S - D A C A( F i g u r e2 ) :ad o s e
that produces maximal damage in the least sensitive RD
cells. Whilst DNA damage is evident after just 1 h in the
sensitive RH30 cells, its appearance is delayed 24 h in the
resistant Res30 cells, and then reaches only 10% of the
damage induced with a 4 μM dose of AS- DACA after 48
h: a value only ~15% of that of the parental RH30 cell
line (Figure 2). Interestingly, DNA breaks are detected in
RD cells after just 4 h, despite the drug concentration
being approximately 190 times lower than its IC50 in this
cell line. At 48 h the level of DNA damage reached
40% of the maximum caused by a 4 μMd o s e( pv a l u e=
1.25 × 10
-5, Students t-test). These findings demonstrate
that the level of DNA damage is directly proportional to
the IC50 of AS-DACA in each cell line.
Since AS-DACA is a known substrate of the ABC trans-
port proteins [17], we explored the influence of a represen-
tative transporter, MRP1 (ABCC1) on AS-DACA activity
in our sensitive and resistant RMS cell lines. In non-drug-
treated cells, immunofluorescence microscopy of the
MRP1 protein shows diffuse cytoplasmic localization in
both RD and RH30 cells (Figure 3A), whereas in Res30
cells, MRP1 is localized in a punctuate fashion in the peri-
nuclear region, suggestive of vesicular localization (arrows,
Figure 3A). After 16 h exposure to AS-DACA there was no
change in MRP1 localization in RD or Res30 cells, but, in
contrast, MRP1 in RH30 cells now localises in a punctuate
perinuclear pattern, similar to that observed in untreated
Res30 cells (arrow, Figure 3A). Western blot analysis of
MRP1 expression levels shows a significant rise in RD and
RH30 cells following a 16 h exposure to twice the IC50 of
AS-DACA for each cell line (8 μM and 40nM respectively)
(p value = 0.02 and 0.002 respectively, Students t-test).
(Figure 3B).
In contrast, although MRP1 is well-expressed in Res30
cells, its level decreases following exposure to the drug
(Figure 3B). Exposure to the MRP1 inhibitor R-verapamil
at concentrations of 1 and 10 μM fails to alter AS-
DACA-induced cytotoxicity (Figure 3C), indicating the
differential toxicity of AS-DACA in the RMS cells is not
simply explained by a classical understanding of drug
resistance involving MRP1.
Taking advantage of the fluorescent properties of AS-
DACA [17] to assess its intracellular distribution in
RMS cells, we exposed cells to 2 μMA S - D A C Af o r4h
and excited in the UV range (330-385 nm), to show, as
anticipated, that the drug accumulates in the nucleus
(Figure 4). Unexpectedly, however, AS-DACA was also
observed to accumulate in punctate structures within
the cytoplasm. As highlighted in the true colour photo-
graphs of Figure 4A, AS-DACA fluoresces green when
localized to the nucleus, and blue when accumulated in
small vesicle-like structures distributed throughout the
cytoplasm in both cell lines. Interestingly, there is no
evidence of vesicle accumulation of doxorubicin in RD
and RH30 cells (Figure 4A inset), which hints at a differ-
ent mechanism for accumulation, perhaps reflecting the
different charge states of AS-DACA and the anthracy-
cline. These findings prompted us to examine the fluor-
escence properties of AS-DACA as a function of pH,
and Figure 4B shows its emission spectrum in the range
410 to 510 nm when excited in the UV at 260 nm. As
the pH is lowered from 6.8 to 6.2, the green emission
peak around 485 nm remains essentially unchanged, but
the intensity of the blue emission at 440 nm increases
substantially to become the dominant feature in this
region of the spectrum. This spectral change occurs in
the pH range where the acridine chromophore becomes
protonated (pK of 5.2) [10], and, in consequence, pro-
vides a measure of the charged state of the ligand. Thus,
with excitation in the UV, fluorescence microscopy
reveals the presence of AS-DACA in the nucleus where
it is bound to DNA as a monocation [12] and fluoresces
green; and in acidic cytoplasmic vesicles where it is a
blue-fluorescing dication (Figure 4A and 4B).
Figure 2 Levels of phosphorylated H2A.X (gH2A.X) were
determined using ELISA for the RMS cell lines RD, RH30, and
Res30 following exposure to 20 nM of AS-DACA over time.
Levels were calculated as percentages of gH2AX detected after
48 h-exposure to 4 μM AS-DACA. Error bars are SEM for two
experiments performed in triplicate providing six independent
readings per value.
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in the distribution of AS-DACA between the nucleus
and vesicular structures in the two RMS cells lines is
responsible for their differential sensitivity to AS-DACA
toxicity. In addition, we were interested in discovering
which of the cellular compartments is first to accumu-
late AS-DACA. Accordingly, we used a deconvolution
microscope, equipped with computerized exposure con-
trol during imaging, for a more precise rendering of AS-
DACA fluorescence. This was especially useful following
the short treatment times designed to highlight the
agents early accumulation throughout the cell. Figure
4C shows the intracellular distribution of 2 μMA S -
DACA following a 10 min incubation, where it can be
seen that AS-DACA can indeed be detected in both the
nucleus (green) and vesicles (blue) of both RMS cell
lines under these rapid-uptake conditions. The appear-
ance of blue cytoplasmic structures occurs in both sensi-
tive and resistant cell lines, indicative of accumulation
into acidic vesicles. On rare occasions, in both cell lines,
only blue vesicles can be detected, indicating vesicle
accumulation prior to nuclear binding (Figure 4C
arrows). To provide independent evidence that the vesi-
cles into which AS-DACA accumulates really are acidic,
we treated cells with both AS-DACA and LysoTracker™
Red, a fluorescent dye known to accumulate within
acidic compartments. Co-localization of LysoTracker™
Red and AS-DACA was observed in the majority of
Figure 3 Assessment of Multidrug Resistance Associated Protein (MRP1) in RMS cell lines. (A) MRP1 expression determined by indirect
immunofluorescense microscopy showing intracellular distribution of MRP1 (green) in RMS cells following treatment with AS-DACA. Co-stained
with the nuclear stain DAPI (blue). (B) Levels of MRP1 were determined by Western blot before (-), and after (+), exposure to AS-DACA (2 × IC50
for 16 h). Densitometry was performed on triplicate blots with band intensity normalized for both background noise and total protein loading
differences as determined by Ponceau S staining. (C) Influence of (R)-verapamil (1 and 10 μM) on AS-DACA cytotoxicity. RD (top) and Res30
(bottom) cells were treated for 72 h with (R)-verapamil whilst being exposed to serially increasing concentrations of AS-DACA. Error bars in (A)
and (C) represent the SEM for three independent experiments.
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Page 4 of 11vesicles (Figure 5A) in both cell types. However, further
digital deconvolution of the microscopic images indi-
cated that co-localization of the two agents is not always
complete, with some vesicles showing only AS-DACA
(blue) accumulation (Figure 5A).
The expression levels of markers specific for vesicles
active at various stages of the membrane trafficking pro-
cess were examined in all RMS cells, after exposure to
double their IC50 for AS-DACA for 16 h. The expres-
sion levels of Early Endosome Antigen 1 (EEA1), Rab5,
Lysosomal-Associated Membrane Protein 1 (LAMP1),
and Rab7, were assessed by Western blot analysis
(Figure 5B). LAMP1, which is associated with both lyso-
somes and late stage endosomes, and Rab7, a protein
associated with late stage endosomes, were shown not
to be differentially expressed in any of the cell lines, and
were minimally affected by drug treatment. However,
expression of EEA1, a marker of early endosomes, is
substantially higher in the resistant RD and Res30 lines,
and the clearly greater signal observed in Res30 cells,
relative to RH30, is unperturbed by an additional over-
night treatment of drug (Figure 5B). Rab5, which is also
associated with early endosomes, shows similarly
marked lower expression in RH30 cells relative to
Res30, although, now, its expression is only marginally
less than in RD cells (Figure 5B).
We hypothesized that the decrease in the amount of
early endosomes in RH30 cells contributes to their sensitiv-
ity to AS-DACA, due to a lack of vesicular sequestration,
which would allow the drug to pass freely throughout the
cell and into the nucleus and surrounding cells. To test
this, we grew RD and RH30 cells as 3-dimensional spher-
oids, and assessed the ability of AS-DACA to pass through
multiple cell layers. Unfortunately Res30 cells were unable
to be grown as spheroids. After 4 h of incubation at
20 μM, the distribution of fluorescence at both emission
wavelengths across the spheroids is equivalent for both cell
lines, with the intensity of nuclear green fluorescence
within 10 μm of the spheroid edge being 10% greater than
that of vesicular blue fluorescence. After 24 h, however, the
distribution of fluorescence across the spheroids is consid-
erably altered. The blue fluorescence is now more intense
than green at the outer edge (10 μm), the difference being
the most pronounced in the RD cells where the peak is
~10% below that of the RH30 cells, indicating a larger
AS-DACA signal in the vesicles. Furthermore, after 24 h,
AS-DACA is seen to penetrate further into the RH30
spheroids, with equivalent levels of both green and blue
fluorescence being found approximately twice as deep into
the cell mass as observed at 4 h. By contrast, in RD cells,
both fluorescence signals are below 30% relative fluores-
cent intensity beyond a penetration distance of 20 μm,
indicating that AS-DACA is unable to penetrate far into
the RD cell mass even after a lengthy incubation. Evidently,
AS-DACA traverses packed RH30 cells much more readily
than packed RD cells, and it is notable that the blue vesicu-
lar signal leads the way into the spheroid masses.
Discussion
The sensitivity of RMS cell lines to new agents may help
identify novel strategies in treatment for this often refrac-
tory sarcoma. Cytotoxins based on acridine-4-carboxamide
chromophores, such as the methyl sulphone derivative of
N-(2-(dimethylamino)- ethyl)acridine-4-carboxamide,
known as AS-DACA (Figure 1A), trap topoisomerase
Figure 4 AS-DACA fluorescence properties. (A) Images of the
intracellular distribution of AS-DACA in RD and RH30 cells captured
using digital colour photography after a 4 h exposure to 2 μM drug.
Images were captured at 600 × magnification. Scale bars represent
10 μm. Inset shows 4 h exposure to 2 μM doxorubicin. (B)
Uncorrected fluorescence emission spectrum of AS-DACA in
solution over the pH range 6.2 to 6.8. Excitation wavelength was
260 nm, lmax for absorption in the UV. (C) Fluorescent micrographs
prepared using a deconvolution microscope for detection of AS-
DACA. Cells were incubated for 10 min at 2 μM and show vesicle
accumulation in RD (left), and RH30 (right) cells. Nuclei with
reduced, or absent, staining are indicated (arrow).
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activity [20]. The 190-fold differential cytotoxic response to
AS-DACA detected between two RMS cell lines (Figure
1B) correlates with the delayed production of double strand
breaks (Figure 2]. The immediate interpretation of this
result is that AS-DACA is being prevented from intercalat-
ing with the DNA and forming cleavable complexes. With
RMS being one of the most common paediatric sarcomas
associated with poor drug response where the presence of
metastatic or disseminated disease confers a worse prog-
nosis [4-7], the drug resistance mechanism identified here
deserves further attention. The derivation of an AS-DACA
resistant RH30 cell line (Res-30) (Figure 1C) which was not
cross resistant to known topoisomerase poisons (Figure
1D) suggests a resistance mechanism peculiar to AS-
DACA was invoked and is suitable for comparison to the
resistant RD cell line. The absence of double strand breaks
in the Res-30 line (Figure 2) indicates extensive impedance
of the agent from its primary cytotoxic target.
Active mechanisms that drive sequestration of weakly
basic compounds into vesicles of the membrane traffick-
ing system are not uncommon. Several of the ABC
transport pumps have been implicated in such mechan-
isms [21,22] and alternative pathways involving the
trans-golgi network [23], lung-resistance-related protein
1 (LRP1) and major vault proteins [24] have been pro-
posed to modify intracellular drug distributions by alter-
ing transport between the nucleus, endosomal vesicles,
lysosomes and the cytoplasm [25]. In 2003, Rajagopal et
al [20] using HeLa cells, showed that MRP1, P-gp and
BCRP were not only localized to membranes of intracel-
lular vesicles but their roles at these sites contributed to
drug resistance phenotypes via sequestration-based
mechanisms. As illustrated in Figure 3 higher levels of
the ABC transport protein MRP1 following treatment
with AS-DACA was detected, typical of a “classical’ mul-
tidrug resistance phenotype in RMS cells. However, this
treatment-induced increased expression of MRP1 in cell
lines does not explain the differential in sensitivity to
AS-DACA induced cell death. Firstly, both RD and
RH30 cell lines demonstrated an equivalent increase in
MRP1 expression (Figure 3B). Interestingly, MRP1 pro-
tein was shown to localize to vesicular membranes in all
three cell lines (Figure 3A) this being most prominent
Figure 5 (A) Arrows indicate co-localization of AS-DACA and LysoTracker™ Red observed in the RD cells. (a) Digitally magnified
photograph with un-altered colour. (b) The green emission has been digitally removed highlighting the pink/purple colour that results from co-
localization of AS-DACA and LysoTracker™ Red. (c) The red wavelengths are then additionally removed, further highlighting sites of co-
localization. (B) Expression levels of Rab5, Early Endosome Antigen 1 (EEA1) Rab 7 and Lysosome- associated Membrane Protein 1 (LAMP1) were
determined by Western blot before (-), and after (+), exposure to AS-DACA (2 × IC50) for 16 h. Tubulin was included as a loading control. Shown
is a single representative blot for at least three independent experiments where the same result was found in each.
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in the derived AS-DACA resistant line Res30 pretreat-
ment. Despite this, the absence of any effects of the
MRP1 inhibitor verapamil on both the AS-DACA resis-
tant lines (Figure 3C), indicating that impedance of
MRP1 activity did not alter AS-DACA toxicity in any
RMS cells.
Classically, vesicle sequestration of the anthracycline
antibiotics appears to be dictated by the “partitioning
theory”. The partitioning theory of drug sequestration,
which was proposed not long after the discovery of the
lysosome in the 1960’s, [25] is still believed to contribute
significantly to drug resistance [26]. This theory is based
upon the principle that weak acids and bases are capable
of readily diffusing lipid bilayer membranes down pH
gradients, rendering these compounds able to accumu-
late in acidic vesicles due to protonation by free H+
ions present in the vesicular lumen. Such ionization ren-
ders the drug impermeable to the membrane and accu-
mulation will continue whilst vesicular H+ ion
concentrations are maintained [23,25-27].
Like the anthracyclines, AS-DACA features a protona-
tion site at the dimethylaminoethyl side chain (Figure
1A) [10]. Fluorescence spectrophotometry indicated that
with a reduction in pH, still within a physiological range
to 6.2, we see a greater intensity of blue fluorescence
from AS-DACA (Figure 4B). Together, the results pre-
sented highlight that AS-DACA is sequestered by acidic
vesicles of the membrane trafficking system limiting its
opportunity to enter the nucleus. Despite this evidence,
nuclear accumulation of AS- DACA as evidenced by
fluorescent microscopy appeared to be unaltered when
examined on a cell-by-cell approach. However, it is
thought that the mechanisms have greater relevance in
the treatment of solid tumours such as RMS where drug
penetration of the tumour mass is obstructed in the
outer layers of the tumour [27]. We have shown that
impaired penetration of AS-DACA into a solid mass of
the resistant RD cells correlates to a reduction of drug
accumulation into the nucleus when compared to the
sensitive RH30 cells, as evidenced by green fluorescence
peaks (Figure 6). From initial drug exposure of the RMS
cells, AS-DACA is captured into acidic vesicles where no
difference was detectable between cell lines after 10min-
utes (Figure 4C). It is only after extended exposure to 24
hours that the spheroids indicate a greater penetrance of
AS-DACA fluorescence into RH30 spheroids implicating
a more efficacious drug-vesicle-transport mechanism in
the sensitive cells or a delayed system leading to drug
sequestration in the resistant cells.
Knockdown of the major vault protein (MVP) using
siRNA disrupted lysosomal uptake of not only doxorubi-
cin, but also the intracellular pH probe LysoSensor and
the lysosomal specific antigen LAMP1. This study
indicated that MVP was integral in redistributing the
drug away from the nucleus to lysosomes [24]. On this
basis, a simple explanation of our findings is that the
distribution of different vesicle types present in the cell
dictates the different response to AS-DACA. Clearly AS-
DACA is being captured into acidic cellular compart-
ments (Figure 4) but which are pre-lysosomal, (Figure
5A). Assessment of protein markers associated with
vesicles of the membrane trafficking system revealed
that reduced expression the early endosomal markers
EEA1 and Rab5 was found in the sensitive RH30 cells
but increased in the AS-DACA resistant Res-30 to level
equal to or above of the RD cell line (Figure 5B). How-
ever, the lysosomal markers LAMP1 and Rab5 were
unchanged between all cell lines. Whether AS-DACA is
merely redistributed away from the nucleus or whether
it is effluxed from the cells remains unknown, but
unlike MRP1, no significant treatment induced change
in expression of these acidic vesicle markers was
observed, indicating that this is an intrinsic difference
between the RD and Rh30 cell lines.
Conclusions
The implication from our findings suggests that reduced
levels of early endosomal vesicles limit the sequestration
and redistribution of AS-DACA away from the nucleus
in RH30 cells and hence does not offer any protection
from the effects of the drug with topoisomerase poison-
ing. Taking the evidence as a whole shows that endoso-
mal vesicle trafficking influences the toxicity of AS-
DACA in RMS cells and highlights potential new biolo-
gical targets worthy of further study.
Interestingly, sequestration of AS-DACA was identi-
fied through the intracellular visualization of the drug.
Most established molecules used to treat cancer how-
ever cannot be visualized and hence similar mechanisms
may go undetected, only manifesting themselves through
a poor tumour response to therapy. The unique fluores-
cence properties of AS-DACA may be exploited in new
and alternative methods of assessing drug penetration,
distribution and the overall pharmacokinetics of the
drug. Hence, we believe that, regardless of the drugs
fate in clinical development, it will provide an invaluable
tool to cancer pharmacology researchers interested in
understanding the pharmacodynamics and pharmacoki-
netics of weakly basic cytotoxic compounds.
Methods
Drugs
AS-DACA was kindly provided by Professor W.A.
Denny from the Auckland Cancer Society Research
Centre, University of Auckland, New Zealand.
®-Verapa-
mil, mitoxantrone, and doxorubicin were purchased
from Sigma-Aldrich Pty Ltd.
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AS-DACA- Resistant Cell Line
RD and RH30 rhabdomyosarcoma cell lines were pur-
chased from ATCC, Virginia, USA and were routinely
tested for mycoplasma contamination as well as growth
consistency prior to establishment and experimentation.
The presence of the t[1:13] translocation was confirmed in
the Rh30 lines. RD cells were maintained in DMEM med-
i u m( I n v i t r o g e n )s u p p l e m e n t e dw i t h1 0 %f e t a lb o v i n e
serum (FBS) and 2 mM glutamine (Sigma-Aldrich). RH30
cells were maintained in RPMI medium (Invitrogen) and
supplemented with 10% FBS and 2 mM glutamine. All cell
Figure 6 AS-DACA (1 μM) penetrates further into spheroids made from the RH30 sensitive cell line. Confocal images of AS-DACA
diffusion into spheroids made from the RD and RH30 cell lines after 4 and 24 h. Fluorescence intensity is shown as % Relative Fluorescence
Intensity compared to distance penetrated into the spheroid for localization in the nucleus and in cytoplasmic vesicles.
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CO2. Three-dimensional multicellular spheroids were cul-
tured by adding 1.5 × 10
5 cells/ml to agarose-coated 96-
well imaging plates (BD Biosciences), and allowed to
aggregate for 96 h, resulting in the formation of a single
spheroid per well [28]. MTT viability assays were per-
formed as previously described [8]. Sigmoidal dose-
response curves were evaluated using GraphPad Prism 4
by a non-linear regression method, and the concentration
of drug that inhibited growth by 50%, the IC50, calculated
for each agent. An RH30 cell line resistant to AS-DACA
was developed by exposing the cells to increasing doses of
the drug. Cells, initially treated with AS-DACA at a con-
centration of 9 nM for 16 h, were exposed to exponentially
increasing doses of drug over 6 months, with at least 1
week recovery between treatments. At various stages,
MTT viability assays were carried out in order to assess
the sensitivity of the cells to AS-DACA. The resulting
resistant cell line, named “Res30’, was found to tolerate 1
μM AS-DACA, and exhibited this level of resistance
throughout the course of all experiments.
DNA Strand Breaks: Enzyme-Linked ImmunoSorbent
Assay [ELISA]
AS-DACA-induced DNA double strand breaks were
assessed by measuring the level of phosphorylated his-
tone H2A.X [29] with the anti-phospho-histone gH2A.X
(S139) primary monoclonal antibody TK-2F1 using an
ELISA kit (Cyclex, Japan) according to the suppliers
instructions. Optical absorbance was determined using a
Labsystems Multiskan Ascent multi-well plate spectro-
photometer at dual wavelengths of 450/540nm. Each
cell line was treated for various times with 20 nM AS-
DACA, and the level of damage compared, as a percen-
tage, to that resulting from a 48 h exposure of the cells
to a saturating dose (4 μM) of AS-DACA.
Spectrofluorimetry
The influence of pH on the fluorescence properties of
AS-DACA was investigated in phosphate buffers, at a
concentration of 10 μM, using a Perkin Elmer LS-50B
spectrofluorimeter equipped with a Starna Fluorimeter
Micro Cell quartz cuvette. Fluorescence emission was
measured from 280 to 800 nm with excitation at 260
nm, lmax for AS-DACA absorbance in the far UV.
Drug Distribution and Intracellular Probes
Cells were passaged at a 1:5 dilution from near-conflu-
ent plates onto glass coverslips placed in the bottom of
the culture plate. They were subsequently grown for 16
h, and subsequently treated with high dose (1-2 μM) of
AS-DACA for short exposures (10 m-4 h), to obtain
optimal images with minimal quenching of fluorescence.
When required, cells were further incubated for 45 min
with LysoTrackerTM Red (Molecular Probes, Invitro-
gen) at a concentration of 100 nM. Cells were then
washed once with ice cold PBS to minimize drug efflux,
and immediately mounted onto glass microscope slides
using FluorSave mounting media (Calbiochem).
Indirect Immunofluorescence - MRP1 Expression
Cells grown on glass coverslips were gently washed
twice in PBS, fixed permanently by incubating with 4%
paraformaldehyde for 20 min, and made permeable by
treatment with 0.2% Triton X-100 for 10 min at room
temperature. They were then washed 3 times with PBS,
and incubated for 1 h at room temperature with MRP1
primary antibody diluted in PBS containing 0.1% BSA.
Cells were washed and incubated with Alexa
488-conju-
gated donkey anti-mouse (1:500) antibody in 0.1% BSA
in PBS for 1 h in the dark. After washing, the cells were
counterstained with 10 nM DAPI diluted in PBS,
washed, and mounted onto microscope slides.
Fluorescence Microscopy
The majority of the fluorescent images were obtained
using a Jenoptik ProgRes CF Scan digital camera on an
Olympus BX50 epifluorescent microscope fitted with a
UPlan FL 60 ×/corr 0.65-1.25 oil objective. A U-
MWIBA3 filter was used for excitation of AS- DACA
within the range 460 to 490 nm, and green emission
detected between 510 and 550 nm. Red fluorescence, of
doxorubicin and LysoTracker™ Red, was detected above
610 nm using a U-MWIY filter with excitation between
545 and 580 nm. UV excitation of AS-DACA at 330 to
385 nm was achieved using a U-MWV filter with all
emissions above 420 nm detected. ProgRes
® V2.5 soft-
ware was used to capture the images. Image enhance-
ment involving colour level adjustment as dictated by the
RGB histogram, was carried out in Adobe Photoshop. No
other computer enhancement was performed. Extensive
photobleaching under continuous UV irradiation proved
troublesome for fluorescence imaging of AS-DACA. To
address this problem, we used a deconvolution micro-
scope, Delta Vision OMX, which provided precise con-
trol of UV excitation exposure and image capture,
allowing visualization of the AS-DACA intra-cellular dis-
tribution following short exposure times. AS-DACA
fluoresced an intense green from excitation at wave-
lengths between 460 and 490 nm, and blue following
excitation between 330 and 385 nm. Images were cap-
tured using true colour photography at 600 × magnifica-
tion, and the displayed pictures are merged images of
both filters with no enhancements performed.
Imaging Drug Penetration into Spheroids
Spheroids were incubated with 10 μMA S - D A C Af o r
24 h and 12-bit confocal images collected on an
Wolf et al. BMC Cell Biology 2011, 12:36
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pus UPLAPO 10 ×/0.40 air objective lens. Scan rates
of 4.0 μs/pixel, 1.5X zoom, Kalman averaging, and
sequential collection of the green and blue channels,
were applied for all images. Excitation and emission
ranges for the 405 nm diode and 488 nm argon lasers,
respectively, were as follows: Ex 405 nm, Em 425-475
nm; Ex 488 nm, Em 500-600 nm. Image planes were
selected approximately 175 μm inside the spheroid to
eliminate edge effects, and reflection imaging was used
to ensure 100% laser penetration and emission at that
depth within the spheroid. The images were not
manipulated in any way, and were analysed using Ima-
g e Js o f t w a r e( N I H ) .Ao n ep i x e l - w i d el i n ew a sd r a w n
through the centre of the spheroid and the fluores-
cence intensity was measured. The values were nor-
malised and the average intensity profiles for each
wavelength were calculated [28]. Greater than 20
spheroids were measured for each cell line.
Western Blot Analysis
Western blot analysis was performed using established
protocols as previously reported [8]. All antibodies to
MRP1, EEA1, Rab5, Rab7, a tubulin [mouse monoclo-
nal] and LAMP1 (rabbit polyclonal) were purchased
from Abcam. Primary antibodies were used at the fol-
lowing dilutions: MRP1 1:500, LAMP1 1 μg/ml, EEA1
1:200, Rab5 and Rab7 3 μg/ml, a tubulin 1:3000. Sec-
ondary antibodies were donkey anti-rabbit-HRP or don-
key anti-mouse-HRP from GE Bioscience diluted to
1:50000.
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